Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Pembrolizumab for the treatment of non-small-cell lung cancer.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.

2.

Identification of a novel RAMP-independent CGRP receptor antagonist.

Zartman CB, Bell IM, Gallicchio SN, Graham SL, Kane SA, Mallee JJ, Rutledge RZ, Salvatore CA, Vacca JP, Williams TM.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6705-8. doi: 10.1016/j.bmcl.2011.09.056. Epub 2011 Sep 21.

PMID:
21982500
3.

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schödel F, Silber JL; Zostavax Protocol 010 Study Group.

Clin Vaccine Immunol. 2008 Feb;15(2):314-9. Epub 2007 Dec 12.

4.

Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.

Shaw AW, Paone DV, Nguyen DN, Stump CA, Burgey CS, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Graham SL, Vacca JP, Williams TM.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4795-8. Epub 2007 Jun 26.

PMID:
17616394
5.

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.

Burgey CS, Stump CA, Nguyen DN, Deng JZ, Quigley AG, Norton BR, Bell IM, Mosser SD, Salvatore CA, Rutledge RZ, Kane SA, Koblan KS, Vacca JP, Graham SL, Williams TM.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5052-6. Epub 2006 Aug 2.

PMID:
16889959
6.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

Williams TM, Stump CA, Nguyen DN, Quigley AG, Bell IM, Gallicchio SN, Zartman CB, Wan BL, Penna KD, Kunapuli P, Kane SA, Koblan KS, Mosser SD, Rutledge RZ, Salvatore C, Fay JF, Vacca JP, Graham SL.

Bioorg Med Chem Lett. 2006 May 15;16(10):2595-8. Epub 2006 Mar 9.

PMID:
16527483
7.

The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.

Bilodeau MT, Rodman LD, McGaughey GB, Coll KE, Koester TJ, Hoffman WF, Hungate RW, Kendall RL, McFall RC, Rickert KW, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2941-5.

PMID:
15125964
8.

Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.

Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.

PMID:
12941314
9.

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.

Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall RC, Mao X, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8.

PMID:
12852948
10.

Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.

Fraley ME, Rubino RS, Hoffman WF, Hambaugh SR, Arrington KL, Hungate RW, Bilodeau MT, Tebben AJ, Rutledge RZ, Kendall RL, McFall RC, Huckle WR, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.

PMID:
12443771
11.

Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors.

Fraley ME, Hoffman WF, Rubino RS, Hungate RW, Tebben AJ, Rutledge RZ, McFall RC, Huckle WR, Kendall RL, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.

PMID:
12217372
12.

Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells.

Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA.

Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53.

PMID:
11755165
13.

Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries.

Edvinsson L, Sams A, Jansen-Olesen I, Tajti J, Kane SA, Rutledge RZ, Koblan KS, Hill RG, Longmore J.

Eur J Pharmacol. 2001 Mar 9;415(1):39-44.

PMID:
11245850
14.

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues.

Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA.

J Biol Chem. 1999 Mar 5;274(10):6453-60.

15.

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.

Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH.

J Pharmacol Exp Ther. 1997 May;281(2):746-52.

PMID:
9152381
16.

RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase.

Amin D, Rutledge RZ, Needle SJ, Hele DJ, Neuenswander K, Bush RC, Bilder GE, Perrone MH.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):233-40.

PMID:
8717165

Supplemental Content

Loading ...
Support Center